Log in

NASDAQ:ACORAcorda Therapeutics News Headlines

$0.78
+0.02 (+2.64 %)
(As of 05/26/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.75
Now: $0.78
$0.79
50-Day Range
$0.74
MA: $0.93
$1.20
52-Week Range
$0.70
Now: $0.78
$10.34
Volume1.66 million shs
Average Volume2.40 million shs
Market Capitalization$37.37 million
P/E RatioN/A
Dividend YieldN/A
Beta1.62

Headlines

Acorda Therapeutics (NASDAQ ACOR) News Headlines

Source:
DateHeadline
 Brokerages Anticipate Acorda Therapeutics Inc (NASDAQ:ACOR) Will Announce Earnings of -$0.39 Per Share Brokerages Anticipate Acorda Therapeutics Inc (NASDAQ:ACOR) Will Announce Earnings of -$0.39 Per Share
www.americanbankingnews.com - May 27 at 4:30 AM
ACOR Acorda Therapeutics, Inc. Common StockACOR Acorda Therapeutics, Inc. Common Stock
www.nasdaq.com - May 21 at 9:41 PM
Short Interest in Acorda Therapeutics Inc (NASDAQ:ACOR) Increases By 8.4%Short Interest in Acorda Therapeutics Inc (NASDAQ:ACOR) Increases By 8.4%
www.americanbankingnews.com - May 21 at 2:24 AM
Acorda Therapeutics Inc (NASDAQ:ACOR) Given Consensus Rating of "Hold" by BrokeragesAcorda Therapeutics Inc (NASDAQ:ACOR) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - May 20 at 2:09 PM
Q2 2020 EPS Estimates for Acorda Therapeutics Inc Lowered by Analyst (NASDAQ:ACOR)Q2 2020 EPS Estimates for Acorda Therapeutics Inc Lowered by Analyst (NASDAQ:ACOR)
www.americanbankingnews.com - May 11 at 3:20 AM
Acorda Therapeutics, Inc. 2020 Q1 - Results - Earnings Call PresentationAcorda Therapeutics, Inc. 2020 Q1 - Results - Earnings Call Presentation
seekingalpha.com - May 8 at 5:34 PM
Acorda Therapeutics Inc (NASDAQ:ACOR) Forecasted to Post FY2022 Earnings of ($0.44) Per ShareAcorda Therapeutics Inc (NASDAQ:ACOR) Forecasted to Post FY2022 Earnings of ($0.44) Per Share
www.americanbankingnews.com - May 8 at 5:05 PM
Wedbush Weighs in on Acorda Therapeutics Incs Q1 2021 Earnings (NASDAQ:ACOR)Wedbush Weighs in on Acorda Therapeutics Inc's Q1 2021 Earnings (NASDAQ:ACOR)
www.americanbankingnews.com - May 8 at 3:48 PM
Acorda Therapeutics (NASDAQ:ACOR) Announces  Earnings ResultsAcorda Therapeutics (NASDAQ:ACOR) Announces Earnings Results
www.americanbankingnews.com - May 7 at 10:15 PM
Acorda (ACOR) Q1 Earnings Lag Estimates, Revenues Fall Y/YAcorda (ACOR) Q1 Earnings Lag Estimates, Revenues Fall Y/Y
www.nasdaq.com - May 7 at 3:54 AM
Acorda Therapeutics (NASDAQ:ACOR) Rating Reiterated by HC WainwrightAcorda Therapeutics (NASDAQ:ACOR) Rating Reiterated by HC Wainwright
www.americanbankingnews.com - May 6 at 10:55 PM
 Analysts Anticipate Acorda Therapeutics Inc (NASDAQ:ACOR) Will Announce Quarterly Sales of $39.34 Million Analysts Anticipate Acorda Therapeutics Inc (NASDAQ:ACOR) Will Announce Quarterly Sales of $39.34 Million
www.americanbankingnews.com - May 6 at 4:24 AM
BRIEF-Acorda Reports First Quarter 2020 Financial Results And Provides Business UpdateBRIEF-Acorda Reports First Quarter 2020 Financial Results And Provides Business Update
www.reuters.com - May 5 at 10:58 PM
Acorda Therapeutics, Inc. (ACOR) CEO Ron Cohen on Q1 2020 Results - Earnings Call TranscriptAcorda Therapeutics, Inc. (ACOR) CEO Ron Cohen on Q1 2020 Results - Earnings Call Transcript
seekingalpha.com - May 5 at 10:58 PM
Acorda Therapeutics (ACOR) Reports Q1 Loss, Misses Revenue EstimatesAcorda Therapeutics (ACOR) Reports Q1 Loss, Misses Revenue Estimates
finance.yahoo.com - May 5 at 10:58 PM
Acorda Therapeutics EPS misses by $0.10, misses on revenueAcorda Therapeutics EPS misses by $0.10, misses on revenue
seekingalpha.com - May 5 at 5:58 PM
Acorda Reports First Quarter 2020 Financial Results and Provides Business UpdateAcorda Reports First Quarter 2020 Financial Results and Provides Business Update
finance.yahoo.com - May 5 at 5:58 PM
United States Metered Dose Inhaler Market (2019 to 2025) - Featuring 3M, Acorda Therapeutics & Adamis Pharmaceuticals Among OthersUnited States Metered Dose Inhaler Market (2019 to 2025) - Featuring 3M, Acorda Therapeutics & Adamis Pharmaceuticals Among Others
finance.yahoo.com - May 5 at 8:42 AM
Zacks: Analysts Anticipate Acorda Therapeutics Inc (NASDAQ:ACOR) Will Announce Earnings of -$0.35 Per ShareZacks: Analysts Anticipate Acorda Therapeutics Inc (NASDAQ:ACOR) Will Announce Earnings of -$0.35 Per Share
www.americanbankingnews.com - May 4 at 7:36 AM
Parkinsons Disease Therapeutics Market Research by Top Key Players, Applications and Forecast Report 2017 - 2025Parkinson's Disease Therapeutics Market Research by Top Key Players, Applications and Forecast Report 2017 - 2025
www.marketwatch.com - April 30 at 5:48 PM
Global Post herpetic Neuralgia Treatment Market 2020 Analysis, Top Manufacturers, Market Size, Share, Growth Factor and Forecast to 2025Global Post herpetic Neuralgia Treatment Market 2020 Analysis, Top Manufacturers, Market Size, Share, Growth Factor and Forecast to 2025
www.marketwatch.com - April 28 at 8:04 AM
Acorda First Quarter 2020 Update: Webcast/Conference Call Scheduled for May 5, 2020Acorda First Quarter 2020 Update: Webcast/Conference Call Scheduled for May 5, 2020
finance.yahoo.com - April 28 at 8:03 AM
Acorda (ACOR) to Report Q1 Earnings: Whats in the Cards?Acorda (ACOR) to Report Q1 Earnings: What's in the Cards?
www.nasdaq.com - April 24 at 3:13 PM
Acorda (ACOR) to Report Q1 Earnings: What's in the Cards?Acorda (ACOR) to Report Q1 Earnings: What's in the Cards?
finance.yahoo.com - April 24 at 3:13 PM
US Sleep-Wake Disorder Market (2019 to 2025) - Featuring Aeroflow, Arena Pharmaceuticals & Acorda Therapeutics Among OthersUS Sleep-Wake Disorder Market (2019 to 2025) - Featuring Aeroflow, Arena Pharmaceuticals & Acorda Therapeutics Among Others
finance.yahoo.com - April 23 at 9:32 AM
Acorda Therapeutics (ACOR) Flat As Market Gains: What You Should KnowAcorda Therapeutics (ACOR) Flat As Market Gains: What You Should Know
finance.yahoo.com - April 16 at 8:08 PM
The Inhaler Market in the United States to 2025 - Featuring 3M, Acorda Therapeutics & Adamis Pharmaceuticals Among Others - ResearchAndMarkets.comThe Inhaler Market in the United States to 2025 - Featuring 3M, Acorda Therapeutics & Adamis Pharmaceuticals Among Others - ResearchAndMarkets.com
www.businesswire.com - April 15 at 1:37 AM
Acorda Therapeutics (ACOR) Stock Moves -0.11%: What You Should KnowAcorda Therapeutics (ACOR) Stock Moves -0.11%: What You Should Know
finance.yahoo.com - April 7 at 9:30 PM
Axsomes AXS-07 Meets Co-Primary Goals in Migraine StudyAxsome's AXS-07 Meets Co-Primary Goals in Migraine Study
finance.yahoo.com - April 7 at 4:30 PM
Mallinckrodt Starts Rolling BLA Filing for StrataGraft TissueMallinckrodt Starts Rolling BLA Filing for StrataGraft Tissue
finance.yahoo.com - April 7 at 4:30 PM
Axsome's AXS-07 Meets Co-Primary Goals in Migraine StudyAxsome's AXS-07 Meets Co-Primary Goals in Migraine Study
finance.yahoo.com - April 7 at 4:30 PM
Immunomedics (IMMU) in Focus: Stock Moves 5% HigherImmunomedics (IMMU) in Focus: Stock Moves 5% Higher
finance.yahoo.com - April 3 at 3:34 PM
Axsomes (AXSM) AXS-05 Fails to Meet Main Goal in TRD StudyAxsome's (AXSM) AXS-05 Fails to Meet Main Goal in TRD Study
www.nasdaq.com - March 31 at 9:21 PM
Freezing Of Gait Treatment Market Trends and Key Players: Acorda Therapeutics, Teva Pharmaceuticals, GYENNO, MedEXO Robotics, APDM,Freezing Of Gait Treatment Market Trends and Key Players: Acorda Therapeutics, Teva Pharmaceuticals, GYENNO, MedEXO Robotics, APDM,
www.marketwatch.com - March 24 at 7:22 AM
What Makes Acorda (ACOR) a New Buy StockWhat Makes Acorda (ACOR) a New Buy Stock
finance.yahoo.com - March 17 at 2:19 PM
Why Is Acorda (ACOR) Down 54.7% Since Last Earnings Report?Why Is Acorda (ACOR) Down 54.7% Since Last Earnings Report?
finance.yahoo.com - March 14 at 1:01 PM
Acorda Therapeutics Inc.Acorda Therapeutics Inc.
www.barrons.com - March 8 at 12:26 PM
Acorda Therapeutics: Crisis Postponed, Inbrija Needs To PerformAcorda Therapeutics: Crisis Postponed, Inbrija Needs To Perform
seekingalpha.com - February 21 at 6:39 PM
Edited Transcript of ACOR earnings conference call or presentation 13-Feb-20 1:30pm GMTEdited Transcript of ACOR earnings conference call or presentation 13-Feb-20 1:30pm GMT
finance.yahoo.com - February 17 at 5:36 PM
Acorda Therapeutics EPS beats by $0.26, beats on revenueAcorda Therapeutics EPS beats by $0.26, beats on revenue
seekingalpha.com - February 14 at 2:21 PM
Acorda (ACOR) Q4 Earnings Top Estimates, Revenues Fall Y/YAcorda (ACOR) Q4 Earnings Top Estimates, Revenues Fall Y/Y
finance.yahoo.com - February 14 at 2:21 PM
BRIEF-Acorda Therapeutics Posts Q4 Earnings Per Share $1.38BRIEF-Acorda Therapeutics Posts Q4 Earnings Per Share $1.38
www.msn.com - February 13 at 12:10 PM
Acorda (ACOR) Beats Earnings & Revenues Estimates in Q4Acorda (ACOR) Beats Earnings & Revenues Estimates in Q4
www.nasdaq.com - February 13 at 12:10 PM
Acorda Therapeutics, Inc. (ACOR) CEO Ron Cohen on Q4 2019 Results - Earnings Call TranscriptAcorda Therapeutics, Inc. (ACOR) CEO Ron Cohen on Q4 2019 Results - Earnings Call Transcript
seekingalpha.com - February 13 at 12:10 PM
Acorda Therapeutics, Inc. 2019 Q4 - Results - Earnings Call PresentationAcorda Therapeutics, Inc. 2019 Q4 - Results - Earnings Call Presentation
seekingalpha.com - February 13 at 12:10 PM
Acorda (ACOR) Beats Earnings & Revenues Estimates in Q4Acorda (ACOR) Beats Earnings & Revenues Estimates in Q4
finance.yahoo.com - February 13 at 12:10 PM
Acorda Therapeutics (ACOR) Reports Q4 Loss, Tops Revenue EstimatesAcorda Therapeutics (ACOR) Reports Q4 Loss, Tops Revenue Estimates
finance.yahoo.com - February 13 at 12:10 PM
Acorda to Present Data at the 3rd Pan American Parkinson’s Disease and Movement Disorders CongressAcorda to Present Data at the 3rd Pan American Parkinson’s Disease and Movement Disorders Congress
www.businesswire.com - February 12 at 7:42 AM
Whats in Store for Acorda (ACOR) This Earnings Season?What's in Store for Acorda (ACOR) This Earnings Season?
www.nasdaq.com - February 10 at 12:50 PM
Earnings Preview: Acorda Therapeutics (ACOR) Q4 Earnings Expected to DeclineEarnings Preview: Acorda Therapeutics (ACOR) Q4 Earnings Expected to Decline
finance.yahoo.com - February 6 at 5:20 PM
This page was last updated on 5/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.